logo

For the Inventor, By the Inventor

Menlo Park, CA, United States of America

Depomed, Inc.


USPTO Granted Patents = 51

% Expired Patents = 70.6



Trademarks = 11

Forward Citations = 2,171

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Bret Berner (29 out of 65 patents)

silverMedal Sui Yuen Eddie Hou (24 out of 27 patents)

bronzeMedal Gloria Gusler (17 out of 18 patents)

4.  Jenny Louie-Helm (14 out of 14 patents)

5.  John N Shell (9 out of 9 patents)

6.  John W Shell (7 out of 25 patents)

7.  Jong Lim (4 out of 4 patents)

8.  Chien-Hsuan Han (4 out of 7 patents)

9.  Monica L Reid (4 out of 4 patents)

10.  Peter James Watts (3 out of 23 patents)

11.  Jonathan David Castile (3 out of 9 patents)

12.  Alan Smith (3 out of 21 patents)

13.  Cuiping Chen (3 out of 5 patents)

14.  Micheline Markey (3 out of 3 patents)

15.  William Columbus Ian Lafferty (2 out of 3 patents)


Core Competencies:
Gastric Retentive
Oral Dosage Form
Pharmaceutical Compositions
Extended Release
CNS Disorders
Dual Drug Dosage
Zero-Order Release
Gabapentin
Non-Opioid Analgesics
Opioid Analgesics
Pain Management
GABA Analogs

51 patents:

1. 9980903 - Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract (2018-05-29),
2. 9937142 - Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders (2018-04-10),
3. 9814705 - Intranasal spray device containing pharmaceutical composition (2017-11-14),
4. 9801816 - Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract (2017-10-31),
5. 9597338 - Shell-and-core dosage form approaching zero-order drug release (2017-03-21),
6. 9572780 - Dual drug dosage forms with improved separation of drugs (2017-02-21),
7. 9566258 - Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders (2017-02-14),
8. 9561200 - Method of treating post-surgical acute pain (2017-02-07),
9. 9301934 - Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract (2016-04-05),
10. 9161911 - Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders (2015-10-20),
11. 9078814 - Intranasal spray device containing pharmaceutical composition (2015-07-14),
12. 9000046 - Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract (2015-04-07),
13. 8999388 - Dual drug dosage forms with improved separation of drugs (2015-04-07),
14. 8945619 - Shell-and-core dosage form approaching zero-order drug release (2015-02-03),
15. 8889176 - Method of managing or treating pain (2014-11-18),
Depomed, Inc. is a pharmaceutical company that develops and commercializes specialty medicines for the treatment of pain, central nervous system disorders, and other related conditions. With a focus on developing proprietary formulations, Depomed aims to provide innovative solutions to improve patients' lives. Through its scientific expertise and strategic partnerships, the company takes a patient-centric approach to deliver high-quality medications. For more information, please visit their website.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Depomed, Inc.
51 Patents

#29 in Menlo Park, CA

#1,618 in California

#6,876 in US

#13,753 in the World

Menlo Park, CA (US)
Menlo Park, CA, United States of America

Depomed, Inc.

Forward Citations = 2,171

27 inventors:

goldMedal Bret Berner (29 out of 65 patents)

silverMedal Sui Yuen Eddie Hou (24 out of 27 patents)

bronzeMedal Gloria Gusler (17 out of 18 patents)

4.  Jenny Louie-Helm (14 out of 14 patents)

5.  John N Shell (9 out of 9 patents)

Please report any incorrect information to [email protected]
Loading…